NANOMICRO(688690)2024-10-29 09:17Financial Performance - The company's operating revenue for Q3 2024 was RMB 20,998.02 million, an increase of 34.61% year-on-year[2] - The net profit attributable to shareholders for Q3 2024 was a loss of RMB 304.78 million, a decline of 142.59% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 965.17 million, a decrease of 644.37% year-on-year[2] - The basic earnings per share for Q3 2024 was -0.0076 RMB, down 142.94% from the previous year[2] - In the first three quarters of 2024, the company achieved operating revenue of RMB 550 million, a year-on-year increase of 21.85%[13] - Net profit attributable to shareholders for the first three quarters was RMB 42.0043 million, a year-on-year increase of 7.75%[13] - The net profit for Q3 2024 was CNY 41,282,330.84, an increase from CNY 28,046,231.10 in Q3 2023, representing a growth of approximately 47.4%[19] - The total comprehensive income for Q3 2024 was CNY 40,776,821.93, compared to CNY 28,748,939.23 in Q3 2023, indicating a year-over-year increase of about 42%[20] Research and Development - The company reported a total R&D investment of RMB 5,161.56 million in Q3 2024, accounting for 24.58% of operating revenue, a decrease of 4.62 percentage points year-on-year[3] - Research and development expenses for Q3 2024 amounted to ¥128,692,421.83, slightly down from ¥128,906,037.89 in Q3 2023[18] Assets and Liabilities - The total assets at the end of the reporting period were RMB 225,773.34 million, an increase of 6.17% compared to the end of the previous year[3] - Non-current assets totaled ¥1,087,968,237.70 as of Q3 2024, an increase from ¥948,091,690.29 in Q3 2023[16] - Total assets reached ¥2,257,733,372.74 in Q3 2024, compared to ¥2,126,568,288.37 in Q3 2023, marking an increase of 6.2%[16] - Total liabilities amounted to ¥405,592,619.31 in Q3 2024, a slight increase from ¥396,404,010.92 in Q3 2023[16] Cash Flow and Investments - Cash and cash equivalents decreased to RMB 254.14 million from RMB 339.76 million at the end of 2023[14] - Cash flow from operating activities for the first nine months of 2024 was CNY 30,123,285.58, slightly down from CNY 30,486,954.85 in the same period of 2023[22] - Cash inflow from investment activities in the first nine months of 2024 was CNY 501,561,954.91, significantly higher than CNY 277,523,786.03 in the previous year[22] - The net cash flow from financing activities for the first nine months of 2024 was -CNY 156,748,958.15, compared to -CNY 5,784,948.29 in the same period of 2023, indicating a substantial increase in cash outflow[22] Acquisitions and Impairments - The company completed the acquisition of a portion of Zhejiang Fuli Analytical Instrument Co., which contributed RMB 45.77 million to the consolidated revenue in Q3 2024[8] - The company recognized a goodwill impairment provision of RMB 23 million for the quarter, significantly impacting net profit[8] - The company recognized goodwill impairment of RMB 23.39 million for the acquisition of Saipu Instruments due to market adjustments in the biopharmaceutical and in vitro diagnostics sectors[13] Revenue and Costs - Total operating revenue for Q3 2024 reached ¥549,753,972.67, an increase of 22% compared to ¥451,155,239.81 in Q3 2023[18] - Total operating costs for Q3 2024 were ¥483,916,410.38, up from ¥422,357,702.51 in Q3 2023, reflecting a 14.6% increase[18] - Operating profit for Q3 2024 was ¥46,121,451.81, compared to ¥33,839,440.19 in Q3 2023, representing a growth of 36.1%[18] - Sales revenue from chromatography fillers and chromatography media decreased by 1.74% year-on-year to RMB 316 million, primarily due to increased economic uncertainty and tightened financing in the biopharmaceutical industry[13] Equity and Shareholder Information - The company's equity attributable to shareholders was ¥1,713,412,547.32 in Q3 2024, up from ¥1,703,527,946.74 in Q3 2023[16] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.1045, up from CNY 0.0966 in Q3 2023, reflecting an increase of approximately 9.9%[20]